Catalyst Pharmaceuticals, Inc. (CPRX)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (NYSE: CPRX). The investigation concerns whether Catalyst and certain of its officers and/or directors have violated federal securities laws.


On October 30, 2019, Catalyst issued a press release announcing “top-line results from CMS-001, a Phase 3 study evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in adults and children aged 2 years and above.”  The press release advised investors that “[w]hile individual patient improvements were observed in some patient sub-groups, the trial did not meet its primary endpoint of subject global impression (SGI) or the secondary endpoint of muscle function measure (MFM) across all tested subtypes.”  On this news, Catalyst’s stock price fell $0.74 per share, or 12.98%, to close at $4.96 per share on October 30, 2019.


If you are aware of any facts relating to this investigation, or purchased Catalyst shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.